101 related articles for article (PubMed ID: 25113280)
1. Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.
Sánchez-Guijo F
Leuk Res; 2014 Oct; 38(10):1156-7. PubMed ID: 25113280
[No Abstract] [Full Text] [Related]
2. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
3. Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Vander Velde N; Chen L; Guo A; Sharma H; Marynchenko M; Wu EQ; Liu J; Yang H; Shi L
J Oncol Pract; 2013 Sep; 9(5):e212-9. PubMed ID: 23943889
[TBL] [Abstract][Full Text] [Related]
4. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia.
Wiggins CL; Harlan LC; Nelson HE; Stevens JL; Willman CL; Libby EN; Hromas RA
Am J Med; 2010 Aug; 123(8):764.e1-9. PubMed ID: 20670732
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
6. Kinase inhibitor therapy in CML: it's what's inside that counts.
Eide CA; Druker BJ; O'Hare T
Oncotarget; 2013 Sep; 4(9):1332-3. PubMed ID: 23934763
[No Abstract] [Full Text] [Related]
7. Molecular response in CML: where is the bar?
Baccarani M; Soverini S
Blood; 2014 Jul; 124(4):469-71. PubMed ID: 25061165
[TBL] [Abstract][Full Text] [Related]
8. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
Cortes J; De Souza C; Ayala-Sanchez M; Bendit I; Best-Aguilera C; Enrico A; Hamerschlak N; Pagnano K; Pasquini R; Meillon L
Cancer; 2010 Nov; 116(21):4991-5000. PubMed ID: 20665487
[TBL] [Abstract][Full Text] [Related]
9. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
10. Imatinib in chronic myeloid leukemia elderly patients.
Gugliotta G; Castagnetti F; Palandri F; Baccarani M; Rosti G
Aging (Albany NY); 2011 Dec; 3(12):1125-6. PubMed ID: 22203437
[No Abstract] [Full Text] [Related]
11. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M; Luciano L; Latagliata R; Castagnetti F; Ferrero D; Cavazzini F; Trawinska MM; Annunziata M; Stagno F; Tiribelli M; Binotto G; Crisà E; Musto P; Gozzini A; Cavalli L; Montefusco E; Iurlo A; Russo S; Cedrone M; Rossi AR; Pregno P; Endri M; Spadea A; Molica M; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Cambrin GR; Isidori A; Sica S; Abruzzese E; Speccha G; Rosti G; Alimena G
Leuk Res; 2014 Oct; 38(10):1173-6. PubMed ID: 25047978
[TBL] [Abstract][Full Text] [Related]
12. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
14. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
15. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation.
Eishei Oskuei A; Makhdoomi K; Abkhiz S; Vossoghian S; Farrokhpour M
Arch Iran Med; 2014 May; 17(5):388-90. PubMed ID: 24784871
[TBL] [Abstract][Full Text] [Related]
17. [Chronic myeloid leukemia and imatinib: Experience at the Lome Campus teaching hospital (Togo)].
Segbena AY; Kueviakoe IM; Agbetiafa K; Padaro E; Layibo Y; Dorkenoo A; Agbo YM; Bories D
Med Sante Trop; 2012; 22(3):307-11. PubMed ID: 23174189
[TBL] [Abstract][Full Text] [Related]
18. CML: live long and prosper.
Larson RA
Blood; 2011 Oct; 118(17):4499-500. PubMed ID: 22033940
[No Abstract] [Full Text] [Related]
19. Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.
Gorkin L; Kantarjian H
Nat Rev Clin Oncol; 2016 May; 13(5):270-2. PubMed ID: 27098218
[TBL] [Abstract][Full Text] [Related]
20. [Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].
Andreeva SV; Drozdova VD
Lik Sprava; 2014; (1-2):55-9. PubMed ID: 24908961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]